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Sialic acids as terminal residues of oligosaccharide chains play
crucial roles in several cellular recognition events. Exploiting
the selective affinity of Achatinin-H toward N-acetyl-9-O-
acetylneuraminic acid-a2-6-GalNAc, we have demonstrated
the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac2-
GPs) on lymphoblasts of 70 children with acute lymphoblastic
leukemia (ALL) and on leukemic cell lines by fluorimetric
HPLC and flow cytometric analysis. This study aims to assess
the structural aspect of the glycotope of Neu5,9Ac2-GPsALL
and to evaluate whether these disease-specific molecules can be
used to monitor the clinical outcome of ALL. The Neu5,9Ac2-
GPsALL were affinity-purified, and three distinct leukemia-
specific molecular determinants (135, 120, and 90 kDa) were
demonstrated bySDS–PAGE,western blotting, and isoelectric
focusing. The carbohydrate epitope ofNeu5,9Ac2-GPsALLwas
confirmed by using synthetic sialic acid analogs. The enhanced
presence of anti-Neu5,9Ac2-GPALL antibody in ALL patients
prompted us to develop an antigen-ELISA using purified
Neu5,9Ac2-GPsALL as coating antigens. Purified antigen was
able to detect leukemia-specific antibodies at presentation of
disease, which gradually decreased with treatment. Longitudi-
nal monitoring of 18 patients revealed that in the early phase of
the treatment patients with lower anti-Neu5,9Ac2-GPs showed
a better prognosis. Minimal cross-reactivity was observed in
other hematological disorders (n¼ 50) like chronic myeloid
leukemia, acute myelogenous leukemia, chronic lymphocytic
leukemia, and non-Hodgkin’s lymphoma as well as normal
healthy individuals (n¼ 21). This study demonstrated the
potential of purified Neu5,9Ac2-GPsALL as an alternate tool
for detection of anti-Neu5,9Ac2-GP antibodies to be helpful for
diagnosis and monitoring of childhood ALL patients.
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Introduction
Childhood acute lymphoblastic leukemia (ALL) is highly
responsive to chemotherapy; with current treatment pro-
tocols, virtually all patients achieve remission and nearly
80% are eventually cured (Campana et al., 2001). How-
ever, the 20% relapse implies that leukemic cells, although
undetectable, are not completely eradicated (Uzunel et al.,
2003). Considering that ~2000 new ALL cases per year
are diagnosed in the United States alone, an urgent need
exists to find easily detectable and stably expressed
leukemia-specific markers, whose altered expression
could be applied for comprehensive and reliable monitor-
ing of ALL (Chan, 2002). The mandatory technical
expertise required for detection of minimal residual dis-
ease limits its widespread applicability. Therefore,
user-friendly techniques should be developed to identify
biochemical markers whose altered expression could be
explored for risk stratification.
Sialic acids are important constituents of the lymphocyte
cell membrane and influence many biological reactions
either by reacting with specific surface receptors or via
masking of carbohydrate recognition sites (Angata et al.,
2002; Kelm and Schauer, 1997; Mandal et al., 2000;
Schauer, 2004; Sinha et al., 2000). Among the diverse deriv-
atives of sialic acid, the most frequently occurring substitu-
tions are O-acetylation at positions C-7, C-8, and C-9 to
form N-acetyl-7-, -8-, and -9-O-acetyl sialic acids, respec-
tively, leading to a family of O-acetylated sialoglycoconju-
gates (Klein and Roussel, 1998; Schauer and Kamerling,
1997). However, because O-acetyl esters from C-7 and C-8
positions are known to spontaneously migrate to C-9 even
under physiological conditions, O-acetylation at C-9 is con-
sidered the most common biologically occurring modifica-
tion (Vandamme-Feldhaus and Schauer, 1998).
Lectins or lectin-like molecules have been used to predict
changes in sialylation patterns (Angata et al., 2002; Mandal
and Mandal, 1990; Mandal et al., 2000; Sinha et al., 1999a).
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A lectin, Cancer antennarius agglutinin, which recognizes
sialic acids that are O-acetylated at both C-4 and C-9 posi-
tions, has been used to identify an O-acetylated disialo-
ganglioside, Neu5,9Ac2-GD3, as a biomarker in human
melanoma cells (Ravindranath et al., 1988). The enhanced
presence of 9-O-acetylated GD3 has been reported in sev-
eraltumors, includingmelanomas,basaliomas,breastcancer,
and tumors of neuroectodermal origin (Fahr and Schauer,
2001; Kohla et al., 2002). In the gastrointestinal tract, the
concentration of O-acetylated sialic acids of colonic mucin
decreases in colorectal cancers and Hirschsprung’s disease
(Aslam et al., 1999; Mann et al., 1997).
9-O-acetylated sialoglycans are detectable at low levels
on human B lymphocytes, (Kamerling et al., 1982) and
altered expression in disease conditions has been found
(Bandyopadhyay et al., 2004; Chava et al., 2002, 2004a;
Mandal et al., 2000; Sharma et al., 1998; Sinha et al.,
1999a). These sialoglycotopes have also been reported on
parasites (Chatterjee et al., 2003; Chava et al., 2004b,c).
However, owing to the lack of detailed biochemical char-
acterization, their biological significance, especially as a
potential biomarker, remains obscure in ALL. The prefer-
ential specificity of a lectin, Achatinin-H, toward
Neu5,9Ac2-a2,6-GalNAc (Mandal and Basu, 1987;
Mandal et al., 1989; Sen and Mandal, 1995) allowed us to
identify these glycotopes on lymphoblasts of ALL patients.
We have reported an increased amount of Neu5,9Ac2-GPs
on erythrocytes (Mandal et al., 1997) and peripheral blood
mononuclear cells (PBMCs) of ALL patients (Mandal et al.,
1997; Pal et al., 2004a; Sinha et al., 1999a,b,c,d). Subse-
quently, we detected an enhanced level of antibodies against
Neu5,9Ac2-GPs in ALL patients as compared to normal
individuals (Pal et al., 2000, 2001, 2004b).
The present study reports (1) confirmation of the occur-
rence of Neu5,9Ac2 on PBMCs of ALL patients by fluori-
metric high-performance liquid chromatography (HPLC)
and flow cytometry using Achatinin-H as a probe; (2) affin-
ity purification of Neu5,9Ac2-GPsALL from PBMC of ALL
patients using Achatinin-H; (3) demonstration of three leu-
kemia-specific Neu5,9Ac2-GPsALL by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE),
western blotting, and isoelectric focusing (IEF); (4) exam-
ination of the structural aspects of the binding of
Neu5,9Ac2-GPsALL with Achatinin-H using synthetic sialic
acid analogs by inhibition enzyme-linked immunosorbent
assay (ELISA); and (5) the potential application of
Neu5,9Ac2-GPsALL to monitor leukemia-specific anti-
bodies at different phases of treatment by an antigen
ELISA. Given the importance of these disease-specific
molecules, we propose that Neu5,9Ac2-GPsALL on lympho-
blasts may serve as potential biomarkers for diagnosis and
monitoring the disease status.
Results
Expression of O-acetylated sialoglycoconjugates on
PBMCs of ALL (PBMCALL) patients as analyzed by
fluorimetric HPLC
The presence of Neu5,9Ac2 on lymphoblasts of ALL
patients was demonstrated by preparing acid hydrolysates
of PBMCs that were analyzed by fluorimetric HPLC. As
shown in Figure 1, the chromatogram exhibited a well-
resolved peak that coincided with Neu5,9Ac2. This peak
disappeared by saponification, thus confirming the pre-
sence of Neu5,9Ac2 on PBMCALL. The peak eluting at
the position of Neu5Ac was confirmed to be this sialic
acid because it was degraded by incubation of the sample
with sialate-pyruvate lyase prior to derivatization. The
Neu5,9Ac2 peak partially disappeard by this treatment,
too. The peak at retention time 18 (Figure 1B, 1C)
represents a reagent peak. The HPLC profile of PBMCs
from a normal individual showed only a minimal amount
of Neu5,9Ac2 as compared to PBMCs from an ALL
patient.
High expression of Neu5,9Ac2-GPs on lymphoblasts of
ALL patients as detected by flow cytometry using
FITC-Achatinin-H
ALL patients were selected based on the binding of their
PBMCs with anti-CD10 and/or anti-CD19 for B-ALL
(n¼ 55) and anti-CD3 and/or anti-CD7 for T-ALL
(n¼ 15). The leukemic blast population ranged from
60% to 97%. A high expression of cell surface
Neu5,9Ac2-GPs on PBMCALL of both B and T lineage
was evidenced by the high binding of fluorescein isothio-
cyanate (FITC)–Achatinin-H being 90.5 5.0% and
94.2 4.2%, respectively (Figure 2). A similar degree of
FITC-Achatinin-H binding was established in B-ALL
cell lines, namely, NALM-6 (68 5.6%) and REH
(90.6 3.4%); T-ALL cell lines, namely, JURKAT (94.2
4.6%), CEMC-7 (86.0 3.6%), MOLT-3 (82.8 3.8%), and
MOLT-4 (93.4 4.6%). In contrast, the binding of
FITC-Achatinin-H to cells from acute myelogenous
leukemia (AML) (n¼ 6), chronic lymphocytic leukemia
(CLL) (n¼ 6), non-Hodgkin’s lymphoma (NHL) (n¼ 5),
chronic myeloid leukemia (CML) (n¼ 5), and normal
donors (n¼ 15) was minimal (4.2 2.7%, 6.5 2.3%,
7.5 2.0%, 2.7 1.2%, and 5.0 2.4%, respectively). The
negligible binding observed with the cell lines U937
(1.6 0.8%), U266 (19 1.1%), TF-1 (3.8 1.5%), and
KG-1A (1.3 0.8%) corresponded to the minimal expres-
sion of Neu5,9Ac2-GPs in allied hematological diseases,
thus establishing Neu5,9Ac2-GPs as a unique biomarker
induced in ALL (Figure 2). The nature of the 9-O-acety-
lated determinant on lymphoblasts was further determined
by using the CD60b-specific monoclonal antibody
UM4D4 (Kniep et al., 1992). The low binding (5.87%) of
CD60b confirmed that negligible amounts of the
ganglioside Neu5,9Ac2-GD3 were present on leukemic
blasts.
To demonstrate the binding specificity of Achatinin-H
toward the 9-O-acetyl moiety, PBMCs from an ALL
patients, at presentation of disease (i.e., before any treat-
ment) were preincubated with a recombinant O-acetyl-
esterase (Figure 2, inset). The resultant de-O-acetylation
caused a drastic reduction in lectin binding from 80.0%
(mean fluorescence intensity was 140) to 20.2% (mean
fluorescence intensity 8.5). The presence of the 9-O-
AcSA glycotope on lymphoblasts of ALL patients was
thus reconfirmed.
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Fig. 1. Determination of Neu5,9Ac2 by fluorimetric HPLC. Representative profile of an HPLC chromatogram of fluorescent derivatives of free sialic
acids derived from (A) BSM as standard, (B) PBMC of ALL before and (C) after preincubation with ammonia vapor (0.1M) and (D) acyl sialate-pyruvate
lyase. Glycosidically bound sialic acids were subjected to acid hydrolysis, derivatised with 1,2-diamino-4,5-methylenedioxybenzene and analyzed as
described in Materials and methods. The peak at retention time 18 in b and c represents the reagent peak.
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Purification of Neu5,9Ac2-GPs from PBMCs of ALL
patients
Clinically confirmed, immunophenotyped children with
B-ALL (n¼ 10) and T-ALL (n¼ 5) with 480% lympho-
blasts (as measured using lineage-specific established anti-
CD antibodies and Achatinin-H) were selected for purifica-
tion of Neu5,9Ac2-GPsALL. Equal amounts of membrane
proteins (0.8 mg) of PBMCs from ALL and normal donors
(n¼ 5) were affinity-purified using Achatinin-H-Sepharose
4B as an affinity matrix. The yield of purified Neu5,9Ac2-
GPs was 3.7-fold higher in ALL patients as compared to
normal donors—0.37 0.15 mg and 0.10 0.05 mg, respec-
tively. The proportion of membrane proteins from ALL
patients that bound to Achatinin-H was 46.54 2.4% as
compared with 12.50 1.30% from normal individuals.
An ELISA using equal amounts (0.4 mg) of purified
Neu5,9Ac2-GPs from ALL patients (Neu5,9Ac2-GPsALL)
and normal donors (Neu5,9Ac2-GPsN) as the coating
antigen showed a ~threefold increase in lectin binding—
OD405nm was 1.34 versus 0.45, which indicates the lower
amount of Neu5,9Ac2-GPs in normal individuals.
Molecular analysis of purified Neu5,9Ac2-GPs
Three distinct leukemia-specific bands corresponding to 135,
120, and 90 kDa were demonstrated in purified Neu5,
9Ac2-GPsALL on SDS–PAGE (Figure 3A) and western
blot using Achatinin-H (data not shown). The presence of
O-acetylation was strengthened by complete abolition of
binding of Achatinin-H following de-O-acetylation with
alkali treatment. In contrast, two common bands corres-
ponding to 140 and 36 kDa (Figure 3) were visible both in
Neu5,9Ac2-GPsN and Neu5,9Ac2-GPsALL.
The molecular nature of these Neu5,9Ac2-GPs was
further investigated on an IEF gel (Figure 3B). Analysis of
Neu5,9Ac2-GPsALL showed five distinct bands, indicating
five different sialoglycoproteins with similar type of
Fig. 2. Comparison of cell surface expression of Neu5,9Ac2-GPs on ALL patients, patients with other hematological disorders, different cell lines, and on
normal donors by single color FACS analysis using FITC-Achatinin-H. Binding of FITC-Achatinin-H (0.10 mg) to PBMCs (1 106) of childhood ALL
patients of B- (n¼ 55) and T-ALL (n¼ 15), normal individuals (N, n¼ 15) along with established B- (NALM-6, REH) and T- (JURKAT, MOLT-3,
MOLT-4) ALL cell lines was determined by single-color flow cytometric analysis as described inMaterials and methods. PBMCs (1 106) from patients
with other hematological disorders (n¼ 22) that included CML (n¼ 5), AML (n¼ 6), CLL (n¼ 6), and NHL (n¼ 5) along with JOK-1 (derived from
peripheral blood of a patient with hairy cell leukemia), U266 (derived from peripheral blood of a patient with an IgE myeloma), U937 (histiocytic
lymphoma), TF-1 (erythroleukemia), and KG-1a (AML) cell lines was also tested with similar dose of FITC-Achatinin-H. Bars depict the mean SD of
percentage of cells expressing Neu5,9Ac2-GPs as evidenced by FITC-Achatinin-H binding. Inset: Demonstration of Neu5,9Ac2-GPs on cell surface of
PBMCs of an ALL patient, at presentration of disease, by flow cytometric analysis. A representative profile of binding of FITC-Achatinin-H (0.10 mg) to
PBMCs (1 106) of an ALL patient before (thick line) and after (thin line) treatment with recombinant 9-O-acetylesterase derived from the HE1 region of
the influenza C esterase gene to remove cell surface 9-O-acetylation as described in Materials and methods. The dotted line represents unstained cells.
The log of fluorescence intensities in arbitrary units is plotted against cell number.
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glycotopes (lane 2). The single bands implied again their
purity and homogeneity. The gel-eluted 120- and 90-kDa
bands showed acidic pI values corresponding to 3.4 and 4.6,
respectively (lanes 4 and 5). On the contrary, Neu5,9Ac2-
GPsN showed the presence of only two bands (lane 3).
Characterization of the carbohydrate epitope of
Neu5,9Ac2-GPsALL by inhibition-ELISA
To study the binding specificity of Neu5,9Ac2-GPsALL, an
inhibition-ELISA was developed with synthetic analogs of
sialic acid, using Achatinin-H as coating antigen (Table I).
Three regions of sialic acid at C-4, C-2, and C-9 were mod-
ified keeping the common core intact. The percent inhibition
(PI) for a particular inhibitor was calculated as follows:
PI ¼ 100 100  OD in presence of inhibitorð½ =
OD in absence of inhibitorÞ
The relative inhibition (RI) was calculated using the following
normalization equation:
RI ¼ 100  PI of an analog at 68 mMð Þ=
PI of MeaNeu5,9Ac2 at 68 mMð Þ
Inhibition was measured at different concentrations of
Me-a-Neu5,9Ac2 (compound 1, 10–68 mM). The highest
inhibition (PI¼ 89.32%) was achieved using 68 mM of
Me-a-Neu5,9Ac2 and the IC50 (concentration needed for
50% inhibition) was found to be 30.11 mM. However, due
to limited stocks of other analogs, a fixed concentration
(68 mM) of all inhibitors was used for determination of
RI. The relative inhibitions of these analogs with reference
to Me-a-Neu5,9Ac2 were calculated using the normaliza-
tion equation and are presented in Table I.
Replacement of the O-acetyl group of compound 1 with a
hydroxyl group (2) and replacement of oxygen by sulfur (3)
or NH (4) at C-9 decreased inhibition to 28%, 20%, and
13%, respectively. Interestingly, introduction of fluorine (F)
into the 9-N-acetyl group of compound 4 at C-9, that is,
compound 5, resulted in a fivefold reduction of inhibition.
A striking difference was observed between compounds
6 and 7 being (71 3.8% versus 2.0 0.8%), where the
O-acetyl group at C-9 of the former had been exchanged
with the propionyl group -O.CO.CH2.CH3. No inhibition
was observed with compounds 8 and 9, possibly due to the
lack of O-acetylation at the C-9 position. Also, replacement
of the CH3 group of compound 2 with hydrogen at C-2
(compound 8) made the carbohydrate noninhibitory.
Bovine submandibular gland mucin (BSM) with a high
Neu5,9Ac2 content was found to be a good inhibitor of
Neu5,9Ac2-GPsALL binding to Achatinin-H. No inhibition
was observed with de-O-acetylated BSM and asialo-BSM,
indicating that the O-acetylated glycotope is the vital com-
ponent for binding of Neu5,9Ac2-GPsALL with Achatinin-H.
Other sialoglycoproteins, such as sheep submaxillary gland
mucin (SSM), human chorionic gonadotropin (HCG),
fetuin, and a1-acid glycoprotein, that have no O-acetylated
sialic acids did not inhibit.
Potential use of purified Neu5,9Ac2-GPs for monitoring
the disease status by an antigen-ELISA
Previous studies from our group have demonstrated
increased antibody titers against Neu5,9Ac2 in sera of ALL
patients (Pal et al., 2000, 2001, 2004b). Therefore, we wished
to examine the reactivity of affinity-purified Neu5,9Ac2-
GPsALL as a novel capture antigen to monitor the disease
Fig. 3. Molecular characterisation of Neu5,9Ac2-GPs present on
PBMCs of an ALL patient. (A) SDS–PAGE (7.5%): A representative
profile of Neu5,9Ac2-GPsALL (lane ALL, 10 mg/lane) and Neu5,
9Ac2-GPsN (lane N, 4 mg/lane) were electrophoresed. The gel was fixed
and stained for protein with Coomassie brilliant blue R-250. Lane M
represents the molecular weight markers. (B) IEF: The purified
Neu5,9Ac2-GPs (2 mg) were applied to an ampholine polyacrylamide
tube gel (4%) in a pH gradient (3.5–10) as described in Materials and
methods. Representative profiles of Neu5,9Ac2-GPsALL and
Neu5,9Ac2-GPsN are shown in lanes 2 and 3, respectively. Lanes 4 and 5
are individual 120- and 90-kDa Neu5,9Ac2-GPsALL that were gel-eluted
from SDS–PAGE analysis. Lane 1 represents the pI markers.
Table I. Inhibitory potency of sialic acid analogs for the binding of
Neu5,9Ac2-GPsALL with Achatinin-H
Sialic acids C-2 C-9 C-4
Relative
inhibition
(%)
1 Me-a-Neu5,9Ac2 CH3 O.CO.CH3 OH 100
2 Me-a-Neu 5Ac CH3 OH OH 28
3 Me-a-Neu5Ac,
9-SAc
CH3 S.CO.CH3 OH 20
4 Me-a-Neu5Ac
-9-NHAc
CH3 NH.CO.CH3 OH 13
5 Me-a-Neu5Ac9
-NHFAc
CH3 NH.CO.CH2F OH 2.8
6 Benzyl-a-Neu4,
5,9Ac3
C6H5CH2 O.CO.CH3 O.CO.CH3 71
7 Benzyl-a-Neu5Ac-
9-O-Propionyl
C6H5CH2 O.CO.CH2.CH3 OH 2
8 Neu5 Ac H OH OH NI
9 Neu4,5Ac2 H OH O.CO.CH3 NI
NI: not inhibited.
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status. A strong binding with sera from untreated patients
(n¼ 70) was observed in contrast to negligible binding with
normal human serum (n¼ 21), mean SD of OD405nm being
1.14 0.12 versus 0.16 0.01, respectively (Figure 4A). With
treatment, the binding gradually decreased in phases B, C,
and D to 0.69 0.01, 0.19 0.01, and 0.12 0.01, respec-
tively (Figure 4B). In patients that relapsed (phase E,
n¼ 10), absorbance increased again to 1.06 0.06. In paral-
lel, sera from patients with other hematological disorders
(such as AML, CML, CLL, and NHL) were examined and
showed no detectable levels of binding (Figure 4A). To mini-
mize the false positivity, the cut-off value was selected as 0.2
based on themeanODþ3 SDobtained fromnormal controls.
A good correlation (r¼ 0.92) was observed between antibody
titers from the same set of patients as determined by both
antigen-ELISA and BSM-ELISA using Neu5,9Ac2-GPALL
and BSM as coating antigens, respectively (Figure 5). The
data were subjected to a one-way analysis of variance with a
post test for linear trend and confirmed a significant decrease
of antibody titers with progress in treatment. Sensitivity,
specificity, efficiency, positive predictive value, and negative
predictive value of both assays are compared (Table II).
Assessment of the anti-Neu5,9Ac2-GPs antibody levels at
early phase of treatment, an indicator for overall
disease-free survival (DFS)
Measurement of the anti-Neu5,9Ac2-GPs antibody levels at
an early phase of treatment (phase B) allowed discrimination
Fig. 4. (A) Diagnostic potential of antigen-ELISA using Neu5,9Ac2-GPsALL as coating antigen. Purified Neu5,9Ac2-GPsALL (0.5 mg) was coated on a
microtiter plates, washed, blocked, and incubated with sera (1:10 diluted) from untreated ALL (n¼ 70) patients along with AML (n¼ 20), CML (n¼ 15),
CLL (n¼ 10), NHL (n¼ 5), and normal individuals (N, n¼ 21) at 4C. After washing, the antigen–antibody complex was detected using HRP-protein A
as described in Materials and methods. Each point is the average of duplicate determinations. (B) Prognostic potential of antigen-ELISA. Sera (1:10
diluted) from clinically confirmed ALL patients at different phases of treatment were allowed to bind with Neu5,9Ac2-GPsALL-coated wells.
Anti-Neu5,9Ac2-GPs antibodies were monitored by an antigen-ELISA. Data are expressed as mean SD of optical density. A, Induction of remission
(phase A, n¼ 70); B, consolidation/early intensification (phase B, 4–8 weeks, n¼ 58); C, period of maintenance therapy (phase C, 8 weeks–2.5 years,
n¼ 40); D, follow-up case (phase D, 2.5 years onward, n¼ 33) and E, patients who relapsed (phase E, n¼ 10).
Fig. 5. Correlation between Neu5,9Ac2-GPs specific antibody levels as
measured by antigen-ELISA and BSM-ELISA using Neu5,9Ac2-GPsALL
and BSM as capture antigens. A correlation graph representing
Neu5,9Ac2-GPs specific antibody (Ab) titers present in ALL patients
(n¼ 70), at presentation of disease, as measured by antigen-ELISA
(y-axis) and BSM-ELISA (x-axis). Purified Neu5,9Ac2-GPsALL (0.5 mg)
was coated on microtiter plates, washed, blocked, and incubated with
untreated ALL sera at 4C. After washing, the bound complex was
detected usingHRP-protein A as described inMaterials and methods.The
antibody titers was similarly quantitated using the same set of ALL
samples by BSM-ELISA in which BSM (1 mg) was used as coating
antigen (Pal et al., 2000).
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between two groups of patients (n¼ 18) who were followed
up for 224 weeks. In one group, children with high antibody
levels (0.6 at OD405nm, n¼ 10) relapsed (10/10), whereas
children showing low antibody titer (50.6 at OD405nm, n¼ 8)
remained in continuous complete remission. This suggests
that monitoring of these anti-Neu5,9Ac2-GPs antibody levels
may serve as an indicator for DFS (Figure 6).
Discussion
Assessment of the O-acetylated sialoglycan profile in ALL
is a relatively new domain in leukemia sialobiology.
Although the increase of Neu5,9Ac2-GPs has been identi-
fied as an important determinant on lymphoblasts (Pal
et al., 2004a; Sinha et al., 1999a), little progress has been
made in examining the structural aspect of the glycotopes of
Neu5,9Ac2-GPs and in evaluating whether these affinity-
purified disease-specific molecules can be harnessed to
monitor the clinical outcome of ALL. In this study, we
have demonstrated an overexpression of Neu5,9Ac2-GPs
in a large patient population, several T- and B-ALL cell
lines, that collectively substantiate that Neu5,9Ac2-GPs are
unique biomarkers of childhood ALL as established by
HPLC and FACS analyses (Figures 1, 2). Abolition of
lectin bindingby esterase-treated cells confirmed the involve-
ment of O-acetylated sialic acid (Figure 2 inset). Addition-
ally, the absence of Neu5,9Ac2-GPs in normal healthy
individuals and other hematological disorders confirmed
their disease specificity (Figure 2). The selective binding
affinity of Achatinin-H enabled the purification of three
new ALL-specific molecules of molecular weight 135, 120,
and 90 kDa having a Neu5,9Ac2a2-6GalNAc moiety as
their binding epitope. They were exclusively present on
PBMCs of ALL patients, that is, absent on normal
PBMCs (Figure 3A–B). In ALL patients, a significant
amount of total membrane protein (2 mg from 107 cells)
was found to be O-acetylated sialoglycoprotein (0.925 mg).
The detection of leukemia-specific bands both on SDS–
PAGE and western blots and their subsequent disappear-
ance after de-O-acetylation confirmed the occurrence of
O-acetylated sialic acid in Neu5,9Ac2-GPsALL.
A major achievement of this investigation is the verifica-
tion of the nature of the glycotope of Neu5,9Ac2-GPsALL
(Table I) by inhibition-ELISA using synthetic sialic acid
analogs that serve as inhibitors preventing binding between
Neu5,9Ac2-GPsALL and Achatinin-H. A comparative ana-
lysis of the inhibitory potency of various sialic acid analogs
showed that Neu5,9Ac2 is the most critical neuraminic acid
derivative for competition, as compound 1 is the strongest
inhibitor (Table I). Interestingly, a minor modification of
this group caused drastic reduction in inhibition, thus con-
firming that O-acetylation at C-9 position is essential for
binding. The introduction of a highly electronegative atom
(F) at C-9 in compound 5 drastically reduced inhibition,
suggesting hindrance of binding. The absence of inhibition
with compounds lacking O-acetylation at C-9, or the 35.5-
fold reduction in inhibition due to the introduction of a
bulky group at C-9, suggests the existence of a smaller
cleft size in the binding pocket. It can be envisaged that
the cleft size around the binding site of C-9 is just right for
an acetyl group, and even minor substitutions hinder bind-
ing. Introduction of a large group like C6H5 at position C-2
in place of a CH3 group reduces the inhibition only from
100% to 71%, indicating that the cleft size around C-2 is
much bigger than that needed to accommodate CH3. At C-4
substitution of H with an acetyl group does not affect the
inhibition properties, suggesting that adequate space for
accommodation is present in this region. In summary, our
data suggest that the region where C-9 is bound is highly
specific for an O-acetyl group and does not allow any
modification of this group, whereas binding criteria in
other regions of the binding cleft are less stringent.
To show the involvement of the Neu5,9Ac2 moiety of
Neu5,9Ac2-GPsALL in Achatinin-H binding, BSM was
used as an inhibitor, which is known to contain this glyco-
sidic group (Sen andMandal, 1995). However, BSM is not a
proper control, as Neu5,9Ac2a2-6GalNAc is only one of the
oligosaccharide structures present along with mono-, di-,
or tri-O-acetylated sialic acid. Ideally, to elucidate the sugar
specificity one should use the disaccharides isolated from
BSM. It is not possible to prepare the disaccharides with
Neu5,9Ac2, because the alkali treatment of BSM required
Table II. Comparison between antigen-ELISA and BSM-ELISA for
detection (by %) of anti-Neu5,9Ac2-GPsALL antibodies present in the sera
of same set of untreated ALL patients
Assay Antigen-ELISA BSM-ELISA
Sensitivity 100 98.92
Specificity 98.21 92.10
Efficiency 98.42 96.94
Positive predictive value 100 96.84
Negative predictive value 97.58 97.22
Fig. 6. DFS curves of patients with ALL categorized according to
Neu5,9Ac2-GPs-specific antibody titer at phase B as evidenced by
antigen-ELISA. Sera from patients (n¼ 18) were longitudinally
monitored for 224 weeks at various time points after chemotherapy and
anti-Neu5,9Ac2-GPs antibody was detected by antigen-ELISA. A few
patients (n¼ 10) persistently showed high antibody titer (OD405nm 0.6)
at phase B associated with significantly poor DFS. In contrast a few
patients (n¼ 8) persistently showed low antibody titer (OD405nm5 0.6)
at phase B and this was associated with good DFS ( p¼ 0.002).
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for the elimination of the O-glycosidically linked disacchar-
ides would destroy the O-acetyl groups. Presently, no
enzyme or process is available for releasing this glycoside
from the sialoglycoprotein. Synthetic analogs are therefore
the only alternative, but presently they are not available.
The detection of residual leukemic cells by FACS analysis
mainly suffers from the lack of leukemia-specific CD mar-
kers. So far, progress in the identification of new leukemia-
specific markers relied on testing the expression of known
CDmarkers (Bjo¨rklund et al., 2003). This approach, largely
based on trial and error, is slow. We believe that purified
and well-characterized Neu5,9Ac2-GPsALL will now be the
new tool to reach the desired goal.
Previous observations suggested that a humoral response
was directed specifically toward Neu5,9Ac2-GPsALL (Pal
et al., 2000, 2001). Accordingly, we developed a BSM-
ELISA for the measurement of this antibody using BSM
as a coating antigen that contains a mixture of mono-, di-,
and tri-O-acetylated forms of Neu5,9Ac2. Therefore, it may
be envisaged that not all forms of Neu5,9Ac2 present in
BSM are equally available for binding with anti-Neu5,
9Ac2-GPs antibodies. Although a comparable correlation
(r¼ 0.92) between antigen and BSM-ELISA was observed,
antigen-ELISA revealed a higher specificity using a similar
set of patients, and it may be considered as better capture
antigen (Figure 5, Table II). The absence of cross-reactivity
with other hematological diseases makes Neu5,9Ac2-
GPsALL a suitable coating antigen for diagnosis and mon-
itoring of ALL (Figure 4A). To the best of our knowledge,
this is the first demonstration of the applicability of these
unique Neu5,9Ac2-GPsALL molecules to monitor the clin-
ical outcome of ALL (Figure 4B).
In a similar assay, following chemotherapy, anti-
Neu5,9Ac2-GP antibody titers progressively decreased,
reflecting clinical remission. However, a few children
showed an increase in OD405nm, which correlated with clin-
ical relapse. Therefore, monitoring of antibody titers using
Neu5,9Ac2-GPsALL as capture antigen may be an alternate
tool to assess the clinical status of patients.
Interestingly, we observed with a small population of
children (n¼ 18) a good correlation of the antibody titers
at early phase of treatment (phase B) with disease status
(Figure 6). High antibody titers at phase B that showed
close association with relapse (n¼ 10) were observed in
55.5% of patients. The relapse rate was 33% during main-
tenance therapy and 22% after completion of therapy. The
higher incidence of relapse observed in these follow-up
studies may be attributed to inclusion of patients irrespec-
tive of the risk factors (Riyat, 1995; Viana et al., 1994).
These patients may benefit from extensive treatment to
avoid relapse. Therefore it may be recommended that
patients with high antibody titers should be closely moni-
tored for recurrence of disease. Additionally, a low-dose
therapy may be considered for patients showing a persisting
low antibody titer. In the population group of our study, we
successfully correlated the antibody titers with the state of
the disease, thus proving the potency of this assay for
monitoring the disease. Of course, the study should be
evaluated with a larger population group. Studies are
ongoing to build a foundation for the predictive value of
these antibodies.
The role of two different Neu5,9Ac2-GPsN, correspond-
ing to 144 kDa and 36 kDa were detected on normal
PBMCs, remains unclear. Earlier results suggest that they
are constitutively present on normal PBMCs. This is
corroborated by the presence of low anti-Neu5,9Ac2-GPs
antibody in normal human serum, indicating that they are
either less immunogenic or inadequately exposed on the cell
surface of normal PBMC (Pal et al., 2000, 2001).
In summary, our results indicate that leukemia-specific
Neu5,9Ac2-GPsALL recognized by Achatinin-H are novel
lymphoblastoid antigens. It may be envisaged that these
antigens will allow designing primers for RT-PCR–based
detection of minimal residual disease. In the future,
development of monoclonal antibodies against these
Neu5,9Ac2-containing glycoproteins will be useful for
immunophenotyping and drug targeting. Studies on the
production of humanized monoclonal antibodies are
under way and will be helpful for future immunotherapy
in childhood ALL.
Materials and methods
Patients
The study population included clinically confirmed ALL
patients at presentation (n¼ 70). The group was made up
of 46 male and 24 female patients, the median age being
6 years (range 0.8–16 years). The median presenting white
blood cell count was 12 109/L (range 0.4–1000 109/L).
A further 141 samples were obtained during chemotherapy,
and subsequently 10 samples were obtained from children
who relapsed. The diagnosis was established by cytological
examination of the bone marrow smears according to the
French-American-British Group recommendations (Burns
et al., 1981), belonging to L1 or L2 and immunophenotyp-
ing using antibodies against terminal deoxynucleotidyl
transferase, cytoplasmic m, surface membrane Ig, CD3,
CD7, CD10, CD19, and CD34. The group included
B-ALL (n¼ 55) and T-ALL (n¼ 15).
Children had been entered into UK ALL X (Eden et al.,
2000) with addition of further drugs, that is, etoposide and
cytosar, for intensification. They were broadly grouped as
follows: induction of remission (phase A, n¼ 70), consolida-
tion/early intensification (phase B, 4–8 weeks, n¼ 58), per-
iod of maintenance therapy (phase C, 8 weeks–2.5 years,
n¼ 40), follow-up case (phase D, 2.5 years onward, n¼ 33),
and patients who relapsed (phase E, n¼ 10). A few patients
(n¼ 18) were longitudinally monitored for 224 weeks.
Normal healthy individuals (n¼ 21) of both sexes and dif-
ferent blood groups and patients with other hematological
disorders (n¼ 50) that included CML (n¼ 15), AML
(n¼ 20), CLL (n¼ 10), and NHL (n¼ 5) served as controls.
Venous blood (3–4 ml) or bone marrow was collected at
Vivekananda Institute of Medical Science (Kolkata, India)
and then sent to the Indian Institute of Chemical Biology,
where PBMCs were separated by Ficoll-Hypaque density
centrifugation; sera or plasma was stored at 20C.
Informed consent was obtained from donors, patients,
and parents or guardians. The study was approved by the
institutional human ethical committee as per protocol of the
Indian Council of Medical Research.
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Probes and reagents
Achatinin-H, a lectin, purified from the hemolymph of the
African giant land snail Achatina fulica, has been shown to
preferentially bind to glycoconjugates with terminal
Neu5,9Ac2-a2,6-GalNAc residues mainly based on inhibi-
tion study with several monosaccharides and sialoglycopro-
teins, for example, BSM, SSM, HCG, fetuin and a1-acid
glycoprotein. BSM having terminal Neu5,9Ac2 and a
subterminal GalNAc in an a2,6-linkage showed highest
inhibition (Sen and Mandal, 1995). SSM, HCG, fetuin,
and a1-acid glycoprotein with terminal sialic acid either in
a2,6- or a2,3-linkage did not show any inhibition,
reconfirming the specificity of Achatinin-H toward
Neu5,9Ac2a2,6GalNAc glycotope (Mandal and Basu,
1987; Mandal et al., 1989; Sen and Mandal, 1995).
The cell lines used included B-ALL (Nalm-6 andREH), T-
ALL (CEM-C7, MOLT 3, MOLT-4, and JURKAT), JOK-
1 (derived from peripheral blood of a patient with hairy cell
leukemia), U266 (derived from peripheral blood of a patient
with an IgE myeloma), U937 (histiocytic lymphoma), TF-
1 (erythroleukemia), and KG-1a (AML). All cell lines
were maintained in RPMI-1640 supplemented with gluta-
mine (2 mM), gentamycin, and 10% heat-inactivated human
AB serum (medium A). Other chemicals and biological
reagents were from Sigma (St. Louis, MO) unless otherwise
stated.
Fluorimetric HPLC analysis of sialic acids
PBMCs (5 108) of ALL patients were extensively washed
in phosphate buffered saline, and the cell pellet was resus-
pended in 1 ml double-distilled water. Cell lysis was com-
pleted by sonication (three pulses of 16 s each, keeping
samples on ice in between). Glycosidically bound sialic
acids were then subjected to acid hydrolysis with an equal
volume of 4 M propionic acid. Samples were heated to 80C
for 4 h, cooled on ice for 10 min, separated into three
portions, and then lyophilized. Controls included (1) sapo-
nification of sialic acids by placing one of the lyophilized
samples in an ammonium atmosphere overnight and (2)
treatment by sialate-pyruvate lyase by resolving a sample
in 250 mM phosphate buffer, pH 7.2, containing 25 mU
lyase and incubation for 2 h at 37C. All samples were then
derivatized with 1,2-diamino-4,5-methylenedioxybenzene
for fluorimetric reverse-phase HPLC analysis (Chatterjee
et al., 2003).
Flow cytometric analysis
The expression of Neu5,9Ac2-GPs on lymphoblasts of ALL
patients was evaluated by flow cytometry (FACS Calibur
flow cytometer) using FITC-Achatinin-H. Briefly, PBMCs
(1 106 cells/100 ml) from both T- and B-ALL patients and
several established cell lines in medium A was blocked
with goat serum (10%) and individually labeled with FITC-
Achatinin-H or phycoerythrin-conjugated anti-CD10, anti-
CD19, anti-CD7 (Pharmingen, SanDiego, CA) in ice for 1 h
(Pal et al., 2000). The cells were washed, fixed in para-
formaldehyde (1%), and analyzed. FITC–bovine serum
albumin (BSA) or FITC-Achatinin-H in the presence of
the inhibitor (BSM) or unconjugated lectin control
(preincubation of cells with Achatinin-H followed by incu-
bation with FITC-Achatinin-H) was used as different sets
of controls. The % positive cells were recorded based on the
threshold or background fluorescence provided by all these
sets of controls, which gave a similar level of background
fluorescence.
Alternatively, cells were incubated with Achatinin-H fol-
lowed by rabbit anti-Achatinin-H polyclonal antibody, and
the bound complex was detected by FITC-conjugated
second antibody. The percentage of lymphoblasts that
bind to this template was calculated relative to appropriate
isotype matched antibodies, which served as background
fluorescence.
The binding was also measured using FITC-labeled anti-
CD60b, a 9-O-acetyl GD3-specific monoclonal antibody.
FITC-IgM served as an isotype control. Analysis and cal-
culations were performed using Cell Quest software.
Esterase treatment of lymphoblasts of ALL patients
The presence of O-acetyl sialoglycan groups on PBMC of
ALL membrane was demonstrated by taking advantage of
the 9-O-acetyl hemagglutinin esterase of influenza C virus
(Chatterjee et al., 2003). It had been originally cloned in an
SV40 vector (Vlasak et al., 1987) to construct a gene con-
sisting of the influenza C virus HE1 domain fused to the
eGFP gene. Briefly, the entire HE1 coding region was iso-
lated as a Sac I/Cla I restriction fragment. The Cla I site was
filled in to allow blunt end ligation with the filled-in BamH I
site immediately upstream of the eGFP gene derived from
plasmid pEGFP-N3 (Clontech Laboratories, Austria). The
resulting chimeric gene contains the entire HE1 domain and
the first four codons of the HE2 domain linked via a five-
codon spacer to the coding region of eGFP. This construct
was ligated into the recombination vector pBakPAK8. The
resulting plasmid pBacPAK-CHE1-eGFP was cotrans-
fected with baculovirus DNA (Pharmingen) into Sf9 cells.
Recombinant baculovirus Bak-CHE1-eGFP was plaque-
purified and used to express the recombinant HE1-eGFP
fusion protein. The expression of the HE-1 domain was
sufficient to obtain a specific 9-O-acetyl esterase activity.
Accordingly, cells (1 106) were incubated with the culture
supernatant (100 ml) containing recombinant protein for 1 h
at 20–25C, washed, and processed for flow cytometric
analysis as described.
Purification of Neu5,9Ac2-GPs
PBMC membranes from clinically confirmed, immunophe-
notyped children of B-ALL (n¼ 10) and T-ALL (n¼ 5), at
presentation of disease, that is, before any drug treatment,
having 480% lymphoblasts (as measured using lineage
specific established anti-CD antibodies and Achatinin-H)
and normal donors (n¼ 5) were prepared according to
Weissman et al. (1988). In brief, cells (1 107) were washed
in ice-cold phosphate buffered saline (1.9 mM disodium
hydrogen phosphate, 154 mM sodium chloride, pH 7.2)
and suspended in lysis buffer containing Tris–HCl
(50 mM, pH 7.6), NaCl (300 mM), Triton X-100 (0.5%),
phenylmethyl sulfonyl fluoride (0.01 M), and iodoaceta-
mide (1.8 mg/ml). Following incubation for 45 min on ice,
the nuclear pellet was discarded by centrifugation at
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15,000 g for 15min at 4C. To the supernatant, SDS (10%)
and sodium deoxycholate (10%) were added to a final con-
centration of 0.2% each, centrifuged, and the supernatant
containing membrane-enriched fraction was stored
at 70C. The purity of membrane fractions was confirmed
by measuring 50 nucleotidase activity, and the protein con-
centration was determined using BSA as the standard.
The purified Achatinin-H was covalently linked to
Sepharose-4B (1.0 mg of Achatinin-H/ml of gel). Equal
amount of membrane fractions (0.8 mg) from each patient
or normal donors were separately passed through this affi-
nity column (1 2 cm) previously equilibrated with Tris-
buffered saline (TBS) containing Tris–HCl (0.05 M), NaCl
(0.15 M), and sodium azide (0.02%), pH 7.2, with CaCl2
(0.03 M) at 4C. After nonspecific washing, bound
Neu5,9Ac2-GPs were eluted with TBS containing sodium
citrate (0.04 M, pH 7.2), dialyzed against TBS at 4C and
stored at 70C. The biological activity of Neu5,9Ac2-
GPsALL and Neu5,9Ac2-GPsN was compared by an ELISA
where equal amounts of purified fractions (0.4 mg/100 ml/
well) were allowed to bind with Achatinin-H on a 96-cell
plates, probed with anti-Neu5,9Ac2-GP antibodies and
processed as described in inhibition-ELISA (see later
discussion).
Molecular analysis of purified Neu5,9Ac2-GPs by
SDS–PAGE, western blot, and IEF
Affinity-purified Neu5,9Ac2-GPs were separated by SDS–
PAGE (7.5%) according to the method of Laemmli (1970)
and stained with Coomassie brilliant blue R-250. For
western blot analysis, Neu5,9Ac2-GPs were transferred
after SDS–PAGE onto nitrocellulose at 100 V for 2 h.
After blocking the nonspecific binding sites with BSA
(10%) in TBS (0.1 M, pH 7.4) the membranes were probed
with Achatinin-H (160 mg/ml) in TBS-BSA-Ca2þ (0.03 M).
After washing, the blot was incubated with rabbit anti-
Achatinin-H (diluted 1:500) at 4C and washed, and the
antigen-antibody complex was detected using horseradish
peroxidase (HRP)–conjugated goat anti-rabbit IgG
(Cappel, St. Louis, MO; 1:10,000). For de-O-acetylation,
the blots were incubated with NaOH (0.1 N) for 45 min at
4C, neutralized, and processed similarly.
Following SDS–PAGE, the 90- and 120-kDa Neu5,9Ac2-
GPALL bands were gel-eluted using an Electro-Eluter
(Model 422; BioRad, Hercules, CA) according to the man-
ufacturer’s instructions and analyzed by IEF on ampholine
polyacrylamide gel (4%) using a Mini-Protean II tube cell
apparatus (BioRad) at a constant voltage of 400 V for 6 h.
The gels were washed with sulfosalicylic acid (5%), metha-
nol (30%), and acetic acid (10%) solution, fixed in trichloro-
acetic acid (10%), and stained with silver nitrate. The
isoelectric point (pI) of individual proteins was determined
as a function of their migration from the cathode using
standard pI markers ranging from 3.5 to 10 (Bio Rad).
Synthesis of sialic acid analogs
Me-a-Neu5,9Ac2 (1) and benzyl-a-Neu4,5,9Ac3 (6) were
obtained by partial acetylation of the respective Neu5Ac
glycoside using acetimidazole. Me-a-Neu5Ac (2) was
prepared as reported earlier (Meindl and Tuppy, 1965;
Kuhn et al., 1966). Me-a-Neu5Ac9-SAc (3) and Me-a-
Neu5Ac9-NHAc (4) were synthesized as previously
described (Brossmer and Gross, 1994; Isecke and Brossmer,
1995). Conversion of Me-a-9-amino-Neu5Ac with nitro-
phenyl fluoroacetate gave the correspondingN-fluoroacetyl
derivative (5). Reaction of benzyl-a-Neu5Ac with propionic
anhydride afforded after purification the corresponding
9-O-propionic ester (7). Catalytic hydrogenation of
benzyl-a-Neu4,5Ac2 produced Neu4,5Ac2 (9). All analogs
were characterized by nuclear magnetic resonance spectro-
scopy and fast atom bombardment mass spectroscopy.
Competitive binding of purified Neu5,9Ac2-GPsALL with
synthetic sialic acid analogs by inhibition-ELISA
To substantiate the binding specificity of purified
Neu5,9Ac2-GPsALL, an inhibition-ELISA was developed.
Several sialic acid analogs (Troncoso et al., 2000) were
used as inhibitors to compare their potency to inhibit bind-
ing of Neu5,9Ac2-GPsALL to immobilized Achatinin-H. A
microtiter plate was coated with Achatinin-H (1 mg/100 ml/
well in 0.05 M TBS, pH 7.4) and incubated overnight at
4C. Following three washes, the wells were blocked with
TBS–2% BSA for 2 h at 25C. A constant amount of
purified Neu5,9Ac2-GPsALL (1 mg/50 ml TBS-BSA) was
preincubated separately with inhibitor (50 ml, 10–68 mM)
in the presence of 30 mM Ca2þ at 4C for 30 min. The
mixture (100 ml) was added to lectin-coated wells, incubated
overnight at 4C, and washed thrice with TBS containing
0.1% Tween-20 (TBS-T). The binding of Neu5,9Ac2-
GPsALL to Achatinin-H was detected by incubating anti-
Neu5,9Ac2-GPsALL antibodies (1 mg), affinity-purified
from sera of ALL patients (Pal et al., 2000), overnight at
4C. The plate was washed thrice with TBS-T, and the
specific antigen–antibody complex was measured
using HRP-conjugated protein A (diluted 1:10,000, Cappel)
and azino-bis-thio-sulfonic acid. The absorbance was
recorded at 405 nm in an ELISA reader.
Based on the long-standing evidence that BSM contains a
high percentage of 9(8)-O-acetylated sialic acid derivatives
as estimated fluorimetrically (Sharma et al., 1998) and by
fluorimetric HPLC (Chatterjee et al., 2003) it was also used
as an inhibitor in the inhibition-ELISA. In parallel, de-O-
acetylated BSM, desialylated BSM, and other sialoglycopro-
teins (such as SSM, HCG, fetuin, and a1-acid glycoprotein)
having no O-acetylated sialic acids were also used.
Monitoring disease status by measuring the reactivity
of Neu5,9Ac2-GPsALL with ALL serum in an
antigen-ELISA
Purified Neu5,9Ac2-GPsALL (0.5 mg/100 ml TBS/well) were
coated overnight on 96-well plate at 4C. Following three
washes with TBS-T, the wells were blocked with 2% BSA.
Sera (diluted 1:10) from ALL patients at different stages of
treatment, and from patients with other hematological dis-
orders and normal donors were added and incubated over-
night at 4C. After washing thrice with TBS-T, the antigen–
antibody complex was detected using HRP-protein A as
described. In addition, anti-Neu5,9Ac2-GPsALL present in
ALL serum was quantified by BSM-ELISA using BSM
(1 mg/100 ml/well) as coating antigen and binding of
S. Pal et al.
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anti-Neu5,9Ac2-GPsALL was measured as previously
described (Pal et al., 2000).
Statistical analysis
Statistical analysis was performed using the Graph-Pad
Prism statistics software program (Graph-Pad Software,
San Diego, CA). Student’s unpaired or paired t-tests were
used. Reported values are two-tailed and p-values lower
than 0.05 were considered statistically significant. The
Spearman correlation test was used for the comparison of
independent variables. Life table analysis according to
Kaplan andMeier were performed for relapse-free intervals
and overall survival.
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